SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

OPSUMIT

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (commercial); Phase 3 pediatric studies completed
Time to market
Already approved and commercially marketed. A pediatric PAH label expansion is possible but its filing/decision timing is unconfirmed in available data.
Why 3/10
No hard, dated binary is confirmed for OPSUMIT within the next ~12 months, the latest FDA actions on record are routine embryo-fetal-toxicity safety-labeling updates (May–June 2026), a pediatric PAH label-expansion filing/PDUFA is NOT confirmed in available data, and OPSUMIT is a small franchise product inside a mega-cap, so the score is capped at 3 (approved/commercializing, no pending regulatory decision evidenced).
Actionable Insight NEUTRAL

Watch for a J&J/Janssen announcement of a pediatric PAH supplemental filing for OPSUMIT, the two supporting Phase 3 pediatric studies (TOMORROW, n=165, and a 7-patient Japanese study) have completed with posted results, so a submission would be the logical next binary, but no PDUFA date is evidenced yet. For a stock trading at $262.37 with a 22-analyst mean target of $272.50 (6.7% implied upside), OPSUMIT-specific news historically moves JNJ by well under ±1-2%, so treat any headline as franchise color, not a swing factor.

Price Chart

Loading chart...

Executive Summary

OPSUMIT (macitentan) is an approved, marketed oral PAH drug developed by Actelion and now owned by Johnson & Johnson (JNJ) through its Janssen arm, confirmed this session by internal trial records listing Actelion and Janssen Pharmaceutical K.K. as sponsors with JNJ as the affected ticker. It is a mature franchise product inside a mega-cap, with completed Phase 3 pediatric trials suggesting a possible label expansion, but no hard regulatory decision is evidenced in the next 12 months. Net read: a steady, low-volatility product with no near-term binary, neutral for JNJ shareholders.

How It Works

OPSUMIT (macitentan) is an oral drug that blocks the action of endothelin, a chemical messenger that tightens blood-vessel walls. In pulmonary arterial hypertension (PAH), a rare disease of abnormally high blood pressure in the lung arteries, this relaxes and widens those vessels, easing the heart's workload. It is part of a class called endothelin receptor antagonists; it is taken once a day by mouth, and because it can harm a developing fetus, it carries a boxed warning restricting use in women who could become pregnant.

Trial Status

Two Phase 3 pediatric PAH studies are COMPLETED with results posted on ClinicalTrials.gov: TOMORROW (NCT02932410, 165 enrolled, sponsored by Actelion, completed 2025-11-27, primary completion 2024-08-28) and a Japanese pediatric study (NCT05167825, 7 enrolled, sponsored by Janssen Pharmaceutical K.K. [JNJ], completed 2025-03-05). The most recent FDA records are safety-labeling updates (May 20 and June 10-11, 2026) reaffirming the embryo-fetal-toxicity boxed warning for macitentan, standard for this drug class, not a new safety signal for the compound.

The Two-Sided Case

▲ Bull Case4
Pediatric growth optionality: two Phase 3 pediatric PAH studies are COMPLETED with posted results, TOMORROW (NCT02932410, 165 enrolled, completed 2025-11-27) and a Japanese study (NCT05167825, completed 2025-03-05, sponsor mapped to JNJ), setting up a potential pediatric label expansion for an already-approved drug.
Analyst backdrop for the owner is supportive: 31 analysts on JNJ split 22 Buy/Strong Buy vs 9 Hold and 0 Sell (period 2026-08-01), with a mean price target of $272.50 (median $280, high $305, low $190) vs a $262.37 price, ~6.7% implied upside.
Institutional accumulation in JNJ in 2026-Q2 13Fs (e.g., T. Rowe Price add of +39.4% of shares, Capital World Investors +29.5%, Norges Bank new position) shows large funds adding exposure to the parent company.
The broader Actelion-origin PAH franchise (bosentan, selexipag, macitentan all appear in local trial data) gives J&J depth in the PAH market, and OPSUMIT remains an oral standard-of-care therapy in the space.
▼ Bear Case5
No confirmed near-term binary: the FDA catalyst dataset shows no OPSUMIT submission or PDUFA in the last 365 days, and a pediatric sBLA timing is unconfirmed, the next hard decision could be >12 months out.
Small weight in a mega-cap: OPSUMIT is one product in JNJ's diversified portfolio; the local 2-year catalyst history shows JNJ FDA-approval days averaged -0.21% (1-day) and +0.05% (5-day) across 11 approvals, so even positive Opsumit headlines rarely move this stock.
Class/generic competition: the older ERA bosentan appears in local trial records mapped to Viatris (VTRS), a signal that generics have commoditized the ERA class, and newer PAH entrants (including injectable/add-on therapies) pressure share in a niche market.
Label restriction: FDA safety-labeling actions in May-June 2026 reaffirm the embryo-fetal-toxicity boxed warning, which restricts use in women of reproductive potential and adds compliance/liability overhead.
Stock-level caution flags (not drug-specific): JNJ's quant composite score is -5 with 30-day estimate revisions of -4 (deteriorating), CEO Joaquin Duato sold ~$32.2M gross of stock on 2026-08-13, and FINRA off-exchange short-sale flow ratio hit 62.4% on 2026-08-17 (daily short-sale flow, not short interest).

Upcoming Catalysts

  • Possible J&J/Janssen announcement of a pediatric PAH supplemental application for OPSUMIT (unconfirmed timing) following completed Phase 3 pediatric trials
  • Quarterly J&J earnings disclosures of pulmonary-hypertension franchise sales (next reports in 2026)
  • Any FDA action on macitentan labeling (routine safety updates have been the only recent FDA records)
  • Watch for competitor readouts in PAH that could pressure franchise share

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov